Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1998 3
2000 1
2001 4
2002 2
2003 3
2004 2
2005 1
2006 1
2009 3
2010 2
2011 3
2012 4
2013 3
2014 7
2015 11
2016 6
2017 10
2018 14
2019 19
2020 10
2021 4
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 33509972

99 results

Results by year

Filters applied: . Clear all
Page 1
A Phase 1 and Biodistribution Study of ABT-806i, an 111In-Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806.
Gan HK, Burge M, Solomon B, Lee ST, Holen KD, Zhang Y, Ciprotti M, Lee FT, Munasinghe W, Fischer J, Ansell P, Fox G, Xiong H, Reilly EB, Humerickhouse R, Scott AM. Gan HK, et al. J Nucl Med. 2021 Jun 1;62(6):787-794. doi: 10.2967/jnumed.120.253146. Epub 2021 Jan 28. J Nucl Med. 2021. PMID: 33509972 Free article. Clinical Trial.
Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody.
Reilly EB, Phillips AC, Buchanan FG, Kingsbury G, Zhang Y, Meulbroek JA, Cole TB, DeVries PJ, Falls HD, Beam C, Gu J, Digiammarino EL, Palma JP, Donawho CK, Goodwin NC, Scott AM. Reilly EB, et al. Mol Cancer Ther. 2015 May;14(5):1141-51. doi: 10.1158/1535-7163.MCT-14-0820. Epub 2015 Mar 2. Mol Cancer Ther. 2015. PMID: 25731184
Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.
Goss GD, Vokes EE, Gordon MS, Gandhi L, Papadopoulos KP, Rasco DW, Fischer JS, Chu KL, Ames WW, Mittapalli RK, Lee HJ, Zeng J, Roberts-Rapp LA, Loberg LI, Ansell PJ, Reilly EB, Ocampo CJ, Holen KD, Tolcher AW. Goss GD, et al. Cancer. 2018 May 15;124(10):2174-2183. doi: 10.1002/cncr.31304. Epub 2018 Mar 13. Cancer. 2018. PMID: 29533458 Free PMC article. Clinical Trial.
ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.
Phillips AC, Boghaert ER, Vaidya KS, Mitten MJ, Norvell S, Falls HD, DeVries PJ, Cheng D, Meulbroek JA, Buchanan FG, McKay LM, Goodwin NC, Reilly EB. Phillips AC, et al. Mol Cancer Ther. 2016 Apr;15(4):661-9. doi: 10.1158/1535-7163.MCT-15-0901. Epub 2016 Feb 4. Mol Cancer Ther. 2016. PMID: 26846818
A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR.
Cleary JM, Calvo E, Moreno V, Juric D, Shapiro GI, Vanderwal CA, Hu B, Gifford M, Barch D, Roberts-Rapp L, Ansell PJ, Xiong H, Ocampo C, Tolcher AW. Cleary JM, et al. Invest New Drugs. 2020 Oct;38(5):1483-1494. doi: 10.1007/s10637-020-00908-3. Epub 2020 Mar 18. Invest New Drugs. 2020. PMID: 32189093 Clinical Trial.
A phase 1 study of ABT-806 in subjects with advanced solid tumors.
Cleary JM, Reardon DA, Azad N, Gandhi L, Shapiro GI, Chaves J, Pedersen M, Ansell P, Ames W, Xiong H, Munasinghe W, Dudley M, Reilly EB, Holen K, Humerickhouse R. Cleary JM, et al. Invest New Drugs. 2015 Jun;33(3):671-8. doi: 10.1007/s10637-015-0234-6. Epub 2015 Apr 17. Invest New Drugs. 2015. PMID: 25895099 Clinical Trial.
99 results